Letermovir prophylaxis for cytomegalovirus in lung-transplant recipients: a comprehensive study with literature review of off-label use and real-world experiences
Open Access
- 5 April 2024
- journal article
- research article
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 24 (1) , 1-9
Abstract
Letermovir, initially approved for cytomegalovirus (CMV) prophylaxis in hematopoietic stem-cell transplantation, has gained attention for off-label use in lung-transplant (LTx) recipients. Given the high susceptibility of LTx recipients to CMV infection, this study explores the effectiveness and safety of letermovir prophylaxis. A retrospective analysis of using letermovir for LTx recipients at Tohoku University Hospital (January 2000 to November 2023) was conducted. Case summaries from other Japanese transplant centers and a literature review were included. Six cases at Tohoku University Hospital and one at Kyoto University Hospital were identified. Prophylactic letermovir use showed positive outcomes in managing myelosuppression and preventing CMV replication. The literature review supported the safety of letermovir in high-risk LTx recipients. Despite limited reports, our findings suggest letermovir’s potential as prophylaxis for LTx recipients intolerant to valganciclovir. Safety, especially in managing myelosuppression, positions letermovir as a promising option. However, careful consideration is important in judiciously integrating letermovir into the treatment protocol.Keywords
Funding Information
- Takeda Science Foundation (Visionary Research 2021)
- Tokyo-Hokenkai Byotai-Seiri Laboratory (Clinical Research Grant 2022)
- The Institute of Development, Aging and Cancer, Tohoku University (2021)
- Japan Society for the Promotion of Science (23K08287)
This publication has 30 references indexed in Scilit:
- Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant RecipientsJAMA, 2023
- Cellular and humoral immune responses after a third dose of SARS-CoV-2 mRNA vaccine in lung transplant recipients in JapanVaccine, 2023
- Efficacy and safety of mRNA SARS-CoV-2 vaccines in lung transplant recipientsJournal of Infection and Chemotherapy, 2022
- Risk factors of breakthrough aspergillosis in lung transplant recipients receiving itraconazole prophylaxisJournal of Infection and Chemotherapy, 2022
- Cytomegalovirus prevention in thoracic organ transplantation: A single-center evaluation of letermovir prophylaxisThe Journal of Heart and Lung Transplantation, 2021
- Drug interaction between letermovir and voriconazole after allogeneic hematopoietic cell transplantationInternational Journal of Hematology, 2021
- Pharmacokinetic Drug‐Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate MofetilThe Journal of Clinical Pharmacology, 2019
- Pharmacokinetics and Tolerability of Letermovir Coadministered With Azole Antifungals (Posaconazole or Voriconazole) in Healthy SubjectsThe Journal of Clinical Pharmacology, 2018
- Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: A single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trialThe Journal of Heart and Lung Transplantation, 2011
- The Indirect Effects of Cytomegalovirus Infection on the Outcome of Organ TransplantationJAMA, 1989